NEW YORK -- Mylan says it will make available a generic version of its EpiPen, as criticism continued to mount over the.
The company said Monday that its U.S. subsidiary will put out a generic version of the EpiPen that will have a list price of $300 for a two-pack. It will be available in both 0.15 mg and 0.30 mg strengths.
Mylan N.V. said that it anticipates having the generic versions available in the next several weeks. It will continue to market and distribute branded EpiPen.
The company charges $608 for a two-pack of the branded EpiPen. Mylan said it will keep in place the $300 savings card for the branded EpiPen and theannounced last week.
In a statement released Monday, Mylan CEO Heather Bresch said the company understands “the deep frustration and concerns associated with the cost of EpiPen® to the patient,” calling the move to sell a generic version “an extraordinary commercial response.”
The consumer watchdog group Public Citizen said the move falls short and highlights the need for more far-reaching reform of prescription drug pricing in the U.S.
“It’s not enough to offer coupons and it’s not enough to offer an overpriced generic version of its own branded product. The company must roll back its unjustified and outrageous price increases,” the group’s president, Robert Weissman, said in a statement.